BUFFALO, N.Y. — In a moment nearly two decades in the making, the U.S. Food and Drug Administration has accepted Athenex Inc.'s application for oral paclitaxel, the oral version of common chemotherapy drug paclitaxel.
Athenex scientists, staff and investors have long believed the therapy will improve cancer care on an international scale, and it was central to attracting hundreds of millions in private funding before the company went public in 2017.
“Intravenous paclitaxel is a foundational chemotherapy in multiple tumor types, and we plan to invest in broadening the label and uses for oral paclitaxel," Athenex chief medical officer Dr. Rudolph Kwan said. You can read the full story on Buffalo Business First's website.
